VRC-07-523

A groundbreaking Phase IIa clinical trial in South Africa has demonstrated that a combination of broadly neutralizing antibodies and immune stimulants may enable some HIV patients to control the virus without daily antiretroviral therapy.

Real-world data presented at CROI 2025 demonstrates zero HIV acquisitions and high persistence with Apretude (cabotegravir LA) for PrEP across diverse populations, reinforcing its effectiveness in HIV prevention.

The FDA has accepted Gilead's NDA for lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP).